Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Alexion fortifies rare blood disorder drugs business

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.

Read More »

Belgium’s UCB to buy Ra Pharmaceuticals

UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.

Read More »

Allogene, Stanford to Develop Better CAR-T Therapies

Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.

Read More »

Lundbeck buys Alder for $2 billion, eyes ‘blockbuster’ migraine therapy

Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.

Read More »

GSK to Acquire Celiac-Focused Sitari Pharmaceuticals

GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.

Read More »

AstraZeneca Bolsters Machine Learning for Drug Development with Schrödinger Deal

AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.

Read More »

Novartis Inks Collaboration & Option Deal with IFM Due

IFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.

Read More »

AbbVie Enters Immuno-Oncology Deal with Idera

Idera Pharmaceuticals announced an immuno-oncology collaboration with AbbVie to evaluate a combination therapy aimed at stimulating the immune system to create an anti-tumor response.

Read More »

Vertex Branches Into Diabetes, Acquiring Semma for $950 Million

Vertex Pharmaceuticals announced a deal to buy Semma Therapeutics, which focuses on using stem cell-derived human islets as a possible cure for type 1 diabetes.

Read More »

Celgene to Harness Immatics’ Adoptive Cell Therapy Program for Solid Tumors

Celgene and Immatics Biotechnologies inked a deal to develop novel adoptive cell therapies targeting multiple cancers.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom